Dual treatment with RGFP966 and CTCL drugs has an additive effect on cell growth.

<p>Growth curves of dual treatment on HH cells or Hut78 cells. Cells were treated once at hour 0 with DMSO, 10 nM Depsipeptide (Depsi), 2 µM 966, or a combination of 2 µM 966 and either Bexarotene, Methotrexate, or ATRA. Untreated cells and DMSO treated cells were used as controls. Cell growth was assessed at 0, 24, 48, and 72 hours after treatment. (A) HH cells (left) or Hut78 cells (right) were treated with 20 µM or 75 µM Bexarotene alone or in combination with 966. (B) Cells were treated with 0.1 µM Methotrexate alone or in combination with 966. DMSO and 1 M Na₂CO₃ served as vehicle controls. (C) Cells were treated with 2 µM ATRA alone or in combination with 966. ATRA was administered at hour 0 and re-dosed at 48 hours after treatment. For (A–C), representative curves are shown from experiments performed in triplicate that are consistent with other biological replicates. Statistical analysis was performed using a two-tail paired T-test and comparing the HDI, CTCL drug, or dual treated cells to DMSO treated cells resulting in the following p values: (A) HH cells (left), Depsi: p = 0.0008, 966: p = 0.003, Bexarotene: p = 0.003, and 966 plus Bexarotene: p = 0.002. For the Hut78 cells (right), Depsi: p = 0.001, 966: p = 0.08, Bexarotene: p = 0.01, and 966 plus Bexarotene: p = 0.009. (B) HH cells (left), Depsi: p = 0.0008, 966: p = 0.003, Methotrexate: p = 0.003, and 966 plus Methotrexate: p = 0.003. For the Hut78 cells (right) Depsi: p = 0.001, 966: p = 0.01, Methotrexate: p = 0.01, and 966 plus Methotrexate: p = 0.004. (C) HH cells (left), Depsi: p = 0.0008, 966: p = 0.003, ATRA: p = 0.002, and 966 plus ATRA: p = 0.0007. For the Hut78 cells (right) Depsi: p = 0.001, 966: p = 0.01, ATRA: p = 0.02, and 966 plus ATRA: p = 0.004.